Lenz Therapeutics, Inc. (LENZ) — 10-Q Filings
All 10-Q filings from Lenz Therapeutics, Inc.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
LENZ Therapeutics Posts Wider Loss Amid VIZZ Commercialization Push
— Nov 5, 2025 Risk: medium
LENZ Therapeutics, Inc. reported a net loss of $16.7 million for the three months ended September 30, 2025, an increase from a net loss of $10.2 million in the -
LENZ Therapeutics' Q2 Losses Widen Amid R&D Spend
— Jul 30, 2025 Risk: high
LENZ Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company posted a net -
LENZ Therapeutics Files Q1 2025 10-Q
— May 7, 2025 Risk: medium
LENZ Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Graphite Bio, Inc. and Integral Medicines, Inc., is -
LENZ Therapeutics Files Q3 2024 10-Q
— Nov 6, 2024 Risk: medium
LENZ Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Graphite Bio, Inc. and Integral Medicines, Inc., -
LENZ Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
— May 8, 2024 Risk:
LENZ Therapeutics, Inc. (LENZ) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. LENZ Therapeutics, Inc. filed a 10-Q report on May 8, 2024, for the
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX